NEPHROLOGY

PAPER - I

NEPHRO/D/13/20/I

Time : 3 hours Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short note on:

| 1. | Peritoneal membrane is a semi permeable membrane. Discuss its:- a) Structure b) Blood supply c) Role of lymphatics in peritoneal dialysis | 4+3+3 |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| 2. | a) What is complement system? b) Discuss the three complement pathways. c) Enumerate four renal diseases associated with genetic dysfunction of complement pathways. | 1+5+4 |
| 3. | a) Discuss the anatomy of podocyte.b) Discuss pathobiology of podocyte injury.c) What are the therapeutic implications of podocyte injury? | 4+3+3 |
| 4. | Discuss pathogenesis, preventive and therapeutic strategy of Adynamic Bone disease. | 4+3+3 |
| 5. | a) Discuss glomerular diseases associated with HIV. b) Outline treatment stragegy of HIV associated nephropathy. c) Discuss renal transplantation for a patient with chronic kidney disease stage 5 with HIV infection. | 3+3+4 |
| 6. | a) Discuss genetics, pathogenesis and pathology of Alport's Syndrome.b) Discuss Apolipoprotein L1. | 7+3 |
| 7. | a) Discuss renin angiotensin aldosterone system.b) What is its role in chronic kidney disease?c) What are the implications of its blockade? | 3+4+3 |
| 8. | Discuss post transplant malignancies under the following heads: a) Incidence b) Risk factors c) Management of lympho proliferative disorder | 4+2+4 |

P.T.O.